The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: Phase I trial

1995 ◽  
Vol 26 (2) ◽  
pp. 111-123 ◽  
Author(s):  
Henry Brem ◽  
Matthew G. Ewend ◽  
Steven Piantadosi ◽  
Jerry Greenhoot ◽  
Peter C. Burger ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Phase I ◽  
Phase I Trial ◽  
Malignant Gliomas ◽  
Newly Diagnosed ◽  
Interstitial Chemotherapy

scholarly journals Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: A Pediatric Brain Tumor Consortium report1

2007 ◽  
Vol 9 (2) ◽  
pp. 145-160 ◽  
Author(s):  
Ian F. Pollack ◽  
Regina I. Jakacki ◽  
Susan M. Blaney ◽  
Michael L. Hancock ◽  
Mark W. Kieran ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Phase I ◽  
Phase I Trial ◽  
Malignant Gliomas ◽  
Pediatric Brain Tumor ◽  
Newly Diagnosed ◽  
Pediatric Brain

scholarly journals ATIM-08. A PHASE I TRIAL OF PEMBROLIZUMAB AND VORINOSTAT COMBINED WITH TEMOZOLOMIDE AND RADIATION THERAPY FOR NEWLY DIAGNOSED GLIOBLASTOMA (NCT03426891)

2018 ◽  
Vol 20 (suppl_6) ◽  
pp. vi2-vi2
Author(s):  
Solmaz Sahebjam ◽  
Peter Forsyth ◽  
Nam Tran ◽  
Sepideh Mokhtari ◽  
John Arrington ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Phase I ◽  
Phase I Trial ◽  
Newly Diagnosed ◽  
Newly Diagnosed Glioblastoma

scholarly journals Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas

2013 ◽  
Vol 15 (6) ◽  
pp. 759-766 ◽  
Author(s):  
Lindsay B. Kilburn ◽  
Mehmet Kocak ◽  
Franziska Schaedeli Stark ◽  
Georgina Meneses-Lorente ◽  
Carrie Brownstein ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Phase I ◽  
Phase I Trial ◽  
High Grade ◽  
Newly Diagnosed ◽  
High Grade Gliomas

scholarly journals A Phase I Trial of Tipifarnib With Radiation Therapy, With and Without Temozolomide, for Patients With Newly Diagnosed Glioblastoma

2011 ◽  
Vol 81 (5) ◽  
pp. 1422-1427 ◽  
Author(s):  
Phioanh Leia Nghiemphu ◽  
Patrick Y. Wen ◽  
Kathleen R. Lamborn ◽  
Jan Drappatz ◽  
H. Ian Robins ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Phase I ◽  
Phase I Trial ◽  
Newly Diagnosed ◽  
Newly Diagnosed Glioblastoma

Phase I Trial Results of Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 Treatment of Patients With Newly Diagnosed Malignant Gliomas

2000 ◽  
Vol 18 (22) ◽  
pp. 3862-3872 ◽  
Author(s):  
Ilkcan Cokgor ◽  
Gamal Akabani ◽  
Chien-Tsun Kuan ◽  
Henry S. Friedman ◽  
Allan H. Friedman ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Phase I ◽  
Phase I Trial ◽  
Radiation Necrosis ◽  
Malignant Gliomas ◽  
Maximum Tolerated Dose ◽  
Hematologic Toxicity ◽  
Newly Diagnosed ◽  
Iodine 131 ◽  
Dose Limiting Toxicity

PURPOSE: To determine the maximum-tolerated dose (MTD) of iodine-131 (131I)–labeled 81C6 antitenascin monoclonal antibody (mAb) administered clinically into surgically created resection cavities (SCRCs) in malignant glioma patients and to identify any objective responses with this treatment. PATIENTS AND METHODS: In this phase I trial, newly diagnosed patients with malignant gliomas with no prior external-beam therapy or chemotherapy were treated with a single injection of 131I-labeled 81C6 through a Rickham reservoir into the resection cavity. The initial dose was 20 mCi and escalation was in 20-mCi increments. Patients were observed for toxicity and response until death or for a minimum of 1 year after treatment. RESULTS: We treated 42 patients with 131I-labeled 81C6 mAb in administered doses up to 180 mCi. Dose-limiting toxicity was observed at doses greater than 120 mCi and consisted of delayed neurotoxicity. None of the patients developed major hematologic toxicity. Median survival for patients with glioblastoma multiforme and for all patients was 69 and 79 weeks, respectively. CONCLUSION: The MTD for administration of 131I-labeled 81C6 into the SCRC of newly diagnosed patients with no prior radiation therapy or chemotherapy was 120 mCi. Dose-limiting toxicity was delayed neurologic toxicity. We are encouraged by the survival and toxicity and by the low 2.5% prevalence of debulking surgery for symptomatic radiation necrosis.

Sign in / Sign up

Export Citation Format

Share Document